ASX:CYC

Cyclopharm Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume10,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.52%
BetaN/A

Receive CYC News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclopharm and its competitors with MarketBeat's FREE daily newsletter.


About Cyclopharm

Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. It offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The company also provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. It serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.83 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Cyclopharm (ASX:CYC) Frequently Asked Questions

What stocks does MarketBeat like better than Cyclopharm?

Wall Street analysts have given Cyclopharm a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cyclopharm wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How often does Cyclopharm pay dividends? What is the dividend yield for Cyclopharm?

Cyclopharm declared a Interim dividend on Tuesday, August 24th. Stockholders of record on Sunday, September 12th will be paid a dividend of 0.005 per share on Sunday, September 12th. This represents a dividend yield of 0.3%. The ex-dividend date of this dividend is Thursday, September 2nd.
View Cyclopharm's dividend history
.

Is Cyclopharm a good dividend stock?

Cyclopharm pays an annual dividend of A$0.01 per share and currently has a dividend yield of 0.52%.
View Cyclopharm's dividend history.

Who are Cyclopharm's key executives?

Cyclopharm's management team includes the following people:
  • Mr. James S. McBrayer F.A.C.I.D., BSPharm, GDM, FAICD, AIM, CEO, MD, Company Sec. & Director (Age 56, Pay $535.93k)
  • Mr. Mathew Farag, Chief Operating Officer
  • Mr. Graham N. Phillips, Fin. Mang.
  • Dr. Mark Doverty, Global Head of Regulatory Compliance & Clinical Research
  • Ms. Sally-Ann Cornelius, Head of Sales
  • Ms. Niamh McAree, Head of Quality and Regulatory
  • Mr. Chris Quinn, Head of Service
  • Ms. Sui Ling Cheah, Financial Controller (Age 51)
  • Mr. Lynn McLauchlin, Gen. Mang. of Canada
  • Mr. Gary T. Somerville, Quality & Regulatory Mang.

Who are some of Cyclopharm's key competitors?

What is Cyclopharm's stock symbol?

Cyclopharm trades on the ASX under the ticker symbol "CYC."

How much money does Cyclopharm make?

Cyclopharm has a market capitalization of $0.00 and generates $20.39 million in revenue each year.

How many employees does Cyclopharm have?

Cyclopharm employs 48 workers across the globe.

What is Cyclopharm's official website?

The official website for Cyclopharm is www.cyclopharm.com.au.

How can I contact Cyclopharm?

The company can be reached via phone at 61 2 9541 0411.


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.